Nautilus Biotechnology, Inc. Comprehensive Income
Nautilus Biotechnology, Inc. (NAUT) reported Comprehensive Income of -$14.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-07-28
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$14.71M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$15.03M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$13.74M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$13.45M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$58.81M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$70.47M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$62.08M.
- Nautilus Biotechnology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$59.59M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.71M 10-Q · filed 2026-07-28 | -$29.74M 10-Q · filed 2026-07-28 | -$43.48M derived: sum of 3 quarters · filed 2026-07-28 | -$56.93M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | -$15.03M 10-Q · filed 2026-04-28 | -$28.77M derived: sum of 2 quarters · filed 2026-04-28 | -$42.22M derived: sum of 3 quarters · filed 2026-04-28 | -$57.37M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$27.19M derived: sum of 2 quarters · filed 2026-02-26 | -$42.33M derived: sum of 3 quarters · filed 2026-07-28 | -$58.81M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$13.45M 10-Q · filed 2025-10-28 | -$28.60M derived: sum of 2 quarters · filed 2026-07-28 | -$45.08M 10-Q · filed 2025-10-28 | -$63.34M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | -$15.14M 10-Q · filed 2026-07-28 | -$31.63M 10-Q · filed 2026-07-28 | -$49.89M derived: sum of 3 quarters · filed 2026-07-28 | -$65.06M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | -$16.48M 10-Q · filed 2026-04-28 | -$34.75M derived: sum of 2 quarters · filed 2026-04-28 | -$49.92M derived: sum of 3 quarters · filed 2026-04-28 | -$67.73M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$33.44M derived: sum of 2 quarters · filed 2026-02-26 | -$51.25M derived: sum of 3 quarters · filed 2026-02-26 | -$70.47M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$15.17M 10-Q · filed 2025-10-28 | -$32.98M derived: sum of 2 quarters · filed 2025-10-28 | -$52.20M 10-Q · filed 2025-10-28 | -$67.45M derived: sum of 4 quarters · filed 2025-10-28 |
| 2024-06-30 | -$17.81M 10-Q · filed 2025-07-31 | -$37.03M 10-Q · filed 2025-07-31 | -$52.28M derived: sum of 3 quarters · filed 2025-07-31 | -$67.80M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | -$19.22M 10-Q · filed 2025-04-29 | -$34.47M derived: sum of 2 quarters · filed 2025-04-29 | -$49.99M derived: sum of 3 quarters · filed 2025-04-29 | -$67.23M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | -$15.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$30.77M derived: sum of 2 quarters · filed 2025-02-27 | -$48.01M derived: sum of 3 quarters · filed 2025-02-27 | -$62.08M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$15.52M 10-Q · filed 2024-10-29 | -$32.76M derived: sum of 2 quarters · filed 2024-10-29 | -$46.83M 10-Q · filed 2024-10-29 | -$60.21M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | -$17.24M 10-Q · filed 2024-07-30 | -$31.31M 10-Q · filed 2024-07-30 | -$44.69M derived: sum of 3 quarters · filed 2024-07-30 | -$59.87M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | -$14.07M 10-Q · filed 2024-04-30 | -$27.45M derived: sum of 2 quarters · filed 2024-04-30 | -$42.63M derived: sum of 3 quarters · filed 2024-04-30 | -$57.53M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | -$13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$28.56M derived: sum of 2 quarters · filed 2024-02-28 | -$43.46M derived: sum of 3 quarters · filed 2024-02-28 | -$59.59M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$15.18M 10-Q · filed 2023-10-31 | -$30.08M derived: sum of 2 quarters · filed 2023-10-31 | -$46.21M 10-Q · filed 2023-10-31 | -$63.08M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | -$14.90M 10-Q · filed 2023-08-02 | -$31.04M 10-Q · filed 2023-08-02 | -$47.90M derived: sum of 3 quarters · filed 2023-08-02 | -$62.40M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | -$16.13M 10-Q · filed 2023-05-02 | -$33.00M derived: sum of 2 quarters · filed 2023-05-02 | -$47.50M derived: sum of 3 quarters · filed 2023-05-02 | -$58.23M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | -$16.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$31.37M derived: sum of 2 quarters · filed 2023-02-23 | -$42.09M derived: sum of 3 quarters · filed 2023-02-23 | -$50.50M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$14.50M 10-Q · filed 2022-11-01 | -$25.23M derived: sum of 2 quarters · filed 2022-11-01 | -$33.64M 10-Q · filed 2022-11-01 | -$39.00M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$10.72M 10-Q · filed 2022-08-02 | -$19.14M 10-Q · filed 2022-08-02 | -$24.50M derived: sum of 3 quarters · filed 2022-08-02 | -$28.48M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$8.41M 10-Q · filed 2022-05-03 | -$13.78M derived: sum of 2 quarters · filed 2022-05-03 | -$17.75M derived: sum of 3 quarters · filed 2022-05-03 | -$21.13M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | -$5.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$9.34M derived: sum of 2 quarters · filed 2022-02-24 | -$12.72M derived: sum of 3 quarters · filed 2022-02-24 | -$15.62M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$3.98M 10-Q · filed 2021-11-02 | -$7.36M derived: sum of 2 quarters · filed 2021-11-02 | -$10.26M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | -$3.38M 10-Q · filed 2021-08-10 | -$6.28M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |